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Abstract
In a climate of economic uncertainty, cost
effectiveness analysis is a potentially important tool
for making choices about health care interventions.
Methods for such analyses are well established, but
the results need to be interpreted carefully and are
subject to bias. Making decisions based on results of
cost-effectiveness analyses can involve setting
thresholds, but for individual patients, there needs to
be disaggregation of benefits and harms included in
a quality adjusted life year to ensure appropriate
consideration of benefits and harms as well as
personal preferences and circumstances.
Background
The current economic news is bad. Expenditure on
health care is under scrutiny in every country and with
predictions of another economic crash comes pressure
on the funding of health care systems - systems that,
according to the World Health Organization http://
www.who.int/topics/health_systems/en/ are meant to
deliver quality service to all people, when and where
they need them.
At the same time, new products - pharmaceuticals,
diagnostic tests, new technologies - continue to be
developed and launched. Health care systems are under
pressure to pay for all of the potential hope that these
provide, sometimes with good reason, sometimes with-
out. This is where cost-effectiveness analysis comes in.
Discussion
In 1990, Detsky and Naglie [1] published one of the first
guides to cost-effectiveness analysis for clinicians. As
they described it, cost-effectiveness analyses compare
the costs and outcomes for a new intervention with an
existing alternative treatment, strategy or intervention.
The two questions such analyses aim to answer are:
how much does the new intervention cost compared
with current practice and is it more effective, and if so,
how much more? The results of these analyses are pre-
sented as additional cost per additional benefit, that is,
additional dollars per unit benefit gained. This is the
incremental cost effectiveness ratio (ICER). Benefits can
be expressed as different outcomes: as change in a phy-
siological or biological unit of measurement (for exam-
ple, change in glycated hemoglobin (HbA1c)), difference
in lives gained (Life Year Gained, LYG), or differences
in quality adjusted life years (QALY). The choice of the
outcome depends on what data exist that can be used in
the evaluation and whether a mathematical model can
be developed that simulates the course of the disease or
condition and its effect on the quality of life. Inputs into
these models are usually derived from multiple sources,
including clinical trials, observational studies and rou-
tine databases, to name just a few. The degree of uncer-
tainty associated with the primary source of information
will contribute to the uncertainty about the results from
the model.
The results of cost-effectiveness analyses should pro-
vide the same information as that used for making deci-
sions about any purchasing choice in every day life. If a
new strategy or potential purchase is more effective and
costs less than the currently available option, it is almost
certainly worth doing. Likewise, if the new strategy is
less effective and more expensive, no one is likely to buy
it. However, the more usual outcome of a cost effective-
ness analysis of a health technology is that the new
technology may be more effective, but costs more. The
judgment that then needs to be made is whether the
benefit obtained is worth the cost and how certain we
can be about that assessment.
A quick literature search suggests that if the number
of publications is an indicator of public interest, then
answering these questions is a key concern of health
care policy makers. A random selection of topics for
such analyses range from the evaluation of different
strategies for lipid lowering [2] to the use (or not) of
radiological evaluation of bronchiolitis in children [3];
from the use of surgical options in the treatment of
chronic back problems [4] to the use of pharmacoge-
netic tests to manage anticoagulation [5]. Health
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technology assessment authorities, organizations mak-
ing coverage decisions, and clinical guideline producers
are the ‘consumers’ of these publications. There has
been considerable debate about the reliability of the
versions published in journals. Udvarhelyi et al. [6]
published one of the first critiques of published cost-
effectiveness analyses in 1992, pointing out the pro-
blems with published analyses compared to optimal
methods and since then many authors have identified
problems with bias in evaluations [7-10]. As the ana-
lyses are often conducted by commercial entities, the
results may favor the product owned by the sponsor
[11-15] but there are also more simple problems
regarding the calculations. Translating a change in
blood pressure into survival gains and then quality
adjusting them requires translation, extrapolation and
mathematical modeling and can go wrong anywhere in
the equations. In the end, the estimate of the size of
the effect of the intervention, however expressed, is
one of the main determinants of the outcome of the
model, so it needs to be examined closely.
To ensure robust analyses and reliable results, those
interested in conducting them have defined methods
and checklists that specify the gold standard for meth-
ods for cost-effectiveness evaluations [16-18]. However,
there are still challenges in applying the results of an
analysis to decisions. For decisions that apply to a public
health care sector, ‘thresholds’ for ‘acceptable’ cost-effec-
tiveness estimates, that is, a specified value for the ICER,
have been suggested by the World Health Organization
(WHO) and used by organizations such as the National
Institute for Health and Clinical Excellence (NICE) in
the UK, and have also been hotly debated [19-22]. One
crucial problem with thresholds is how to set them and
how to apply them. Values and preferences of commu-
nities are much more difficult to determine or quantify,
but may have greater weight in choices about health
care, particularly in tax-payer-funded systems.
One challenge in interpreting and applying the results
from cost-effectiveness analyses is the difference
between the value of an intervention for the population
and the value for an individual patient. For a clinician,
the response and cost and benefit from a particular
intervention for an individual patient may not be well
represented by a cost-effectiveness ratio from a popula-
tion. Ioannidis and Garber [23] point out that cost-effec-
tiveness estimates, particularly those that express the
results as incremental cost per QALY, combine several
different outcomes in the ‘QALY’, including estimates of
benefits and harms that may mean quite different things
for different individuals. Differences in background
health, a person’s aversion to risk, or their personal cir-
cumstances are likely to have a significant effect on how
an individual interprets the tradeoff between benefits,
harms and costs, and thus chooses between treatment
strategies. The solution suggested by Ioannidis and Gar-
ber is to ‘individualize’ the ICER by presenting a per
person benefit in QALYs expressed as days, a ‘per per-
son cost’ as well as evaluating subgroup responses
within populations to allow estimates of variance within
the ‘average’ ICER, to match an individual to a popula-
tion that may be more or less likely to benefit. It would
be interesting to test this approach in real life - persona-
lized medicine based on personalized health economics.
A new discipline to develop, to satisfy the needs of indi-
vidual patients and clinicians, as well as payers and poli-
ticians simultaneously!
Conclusion
Methods for cost effectiveness analysis are well estab-
lished, but published analyses need to be interpreted
carefully. For clinicians, disaggregating the benefits and
harms incorporated into estimates of QALY may inform
judgments about use of health interventions for indivi-
dual patients.
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